Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Investment analysts at Leerink Swann lowered their FY2017 earnings estimates for shares of Zimmer Biomet Holdings in a research note issued on Wednesday, according to Zacks Investment Research. Leerink Swann analyst R. Newitter now anticipates that the medical equipment provider will post earnings of $8.01 per share for the year, down from their prior estimate of $8.21. Leerink Swann currently has a “Outperform” rating and a $146.00 target price on the stock. Leerink Swann also issued estimates for Zimmer Biomet Holdings’ Q4 2017 earnings at $2.08 EPS, Q1 2018 earnings at $1.92 EPS, Q2 2018 earnings at $1.99 EPS, Q3 2018 earnings at $1.90 EPS, Q4 2018 earnings at $2.23 EPS, FY2018 earnings at $8.03 EPS and FY2019 earnings at $8.85 EPS.
Other research analysts also recently issued research reports about the stock. SunTrust Banks, Inc. restated a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet Holdings in a research report on Monday, October 2nd. Gabelli initiated coverage on shares of Zimmer Biomet Holdings in a research report on Thursday, August 24th. They set a “buy” rating and a $142.00 price objective on the stock. Oppenheimer Holdings, Inc. set a $137.00 price target on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a research report on Monday, August 14th. Piper Jaffray Companies reiterated a “buy” rating and issued a $135.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, July 28th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, November 3rd. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $133.71.
ILLEGAL ACTIVITY NOTICE: “FY2017 EPS Estimates for Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Cut by Leerink Swann” was first published by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://weekherald.com/2017/11/15/zimmer-biomet-holdings-inc-zbh-forecasted-to-post-fy2017-earnings-of-8-01-per-share.html.
Zimmer Biomet Holdings (ZBH) opened at $112.21 on Monday. The firm has a market cap of $22,486.66, a P/E ratio of 13.76, a P/E/G ratio of 1.72 and a beta of 1.17. Zimmer Biomet Holdings has a 52-week low of $98.20 and a 52-week high of $133.49. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88.
Zimmer Biomet Holdings (NYSE:ZBH) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.02). The firm had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The company’s quarterly revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.79 EPS.
Institutional investors have recently added to or reduced their stakes in the company. Ingalls & Snyder LLC lifted its holdings in shares of Zimmer Biomet Holdings by 2.6% in the 3rd quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock worth $2,304,000 after acquiring an additional 507 shares during the last quarter. Caxton Associates LP bought a new stake in Zimmer Biomet Holdings during the 1st quarter valued at about $403,000. Koch Industries Inc. lifted its holdings in Zimmer Biomet Holdings by 49,697.3% during the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after buying an additional 1,038,674 shares in the last quarter. Jensen Investment Management Inc. lifted its holdings in Zimmer Biomet Holdings by 24.2% during the 2nd quarter. Jensen Investment Management Inc. now owns 5,850 shares of the medical equipment provider’s stock valued at $751,000 after buying an additional 1,140 shares in the last quarter. Finally, Andra AP fonden lifted its holdings in Zimmer Biomet Holdings by 15.8% during the 2nd quarter. Andra AP fonden now owns 21,300 shares of the medical equipment provider’s stock valued at $2,735,000 after buying an additional 2,900 shares in the last quarter. Hedge funds and other institutional investors own 85.44% of the company’s stock.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.